About Us

Telix Pharmaceuticals was created to deliver on the promise of nuclear medicine


The field of nuclear medicine has historically lacked clinical momentum and commitment to late-stage product development. Our goal is to rectify this for the benefit of patients.

Since the latest edition of Baselworld, in 2015, it also features a new in-house movement, the Calibre MT5612. And it leads us to this simple conclusion: there will be more variations of this movement in the coming years! replicawatches.to Therefore, we imagined the first one, will be with a GMT complication, something that we know to be extremely useful and rather applauded by potential clients – and that its missing in the actual Tudor catalogue (indeed, theres no GMT watches in the current Tudor line up). We also know that the base movement can easily accept extra-complications, like its the case with the North Flag, which features a power reserve.

Latest News


Telix Collaborates with Olivia Newton-John Cancer Research Institute on Brain Cancer Imaging Study

Melbourne (Australia) – 22 December 2021. Telix enters a clinical data access agreement with the Olivia Newton-John Cancer Research Institute...


First Patient Dosed in Study of Targeted Alpha Therapy Candidate for Bladder Cancer

Melbourne (Australia) and Nantes (France) – 21 December 2021. Telix announces that a first patient has been dosed in the...


FDA Approves Telix’s Prostate Cancer Imaging Product, Illuccix®

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 20 December 2021. Telix announces the FDA has approved Illuccix®, Telix’s lead prostate...


TRALA Study of TLX66 in AL-Amyloidosis Presented at ASH 2021

15 December 2021 – Clinical Spotlight | TRALA Study of TLX66 for Autologous Stem Cell Transplantation in AL-Amyloidosis Presented at American Society of...